Abstract 390P
Background
The intensive incidence rate of oropharyngeal cancer in Uzbekistan has increased over the past 7 years from 1.4 to 2.0 per 100,000 population in 2022, and the proportion of active detection has increased from 25.9 to 32.9%.
Methods
A retrospective analysis of the causes and prevalence of oropharyngeal cancer in the Republic of Uzbekistan was performed. The object of the study were 582 patients from database of RSSPMC of Oncology and Radiology of Uzbekistan who were treated for the period 2020-2022. The study of risk factors was carried out according to gradations: smoking, use of a local variety of tobacco - nasvay, alcohol consumption, a history of trauma, a resident of an urban area, working in gas contamination conditions and dustiness. There were 471 men (80.9%), women - 101 (19.1%). The mean age was 47.3±1.5.
Results
A study of geographical indicators demonstrated that the most common oropharyngeal cancer caused by the use of nasvay occurred in patients from the eastern and southern regions of the republic - 327 (56.2%). In these patients, the average duration of tobacco use was more than 7 years. In contrast, poor climatic conditions caused the development of oral cancer in 89 (15.3%) patients from the Aral Sea region (northwest). The remaining 166 (28.5%) patients were in the central regions of Uzbekistan. When studying risk factors, the vast majority of patients (411 (70.6%)) used nasvay as a bad habit. At the same time, 174 (42.3%) of 411 patients also had smoking and alcohol consumption. Despite the impact of the dusty climate in the Aral Sea zone, 81 (91.0%) patients had a history of alcohol consumption, 19 (21.3%) - smoking. 218 (37.5%) urban residents developed oral cancer due to bad habits (smoking - 174, alcohol - 147, nasvay - 53).
Conclusions
Thus, the analysis of the epidemiological aspects of the development of oral cancer in Uzbekistan indicates that this disease is quite widespread and tends to grow. The main factor is bad habits, in particular the widespread use of nasvay. Only, in the urban population, the influence of nasvay on the development of cancer becomes less, but due to the prevalence of smoking and alcohol abuse, it requires further study to identify specific ways to manage oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tashkent medical academy.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract